XmAb24306

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Multiple MyelomaSolid Tumors

Phase 1

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Active, not recruitingNCT04250155

Genentech, Inc.Solid Tumors

Start: 2020-03-09End: 2026-06-15Updated: 2026-02-24

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

CompletedNCT05243342

Genentech, Inc.Multiple Myeloma

Start: 2022-04-28End: 2024-07-10Updated: 2025-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruitingNCT05646836

Genentech, Inc.Multiple Myeloma

Start: 2023-03-21End: 2026-11-18Target: 90Updated: 2026-02-17